Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma

We prospectively evaluated the efficacy and safety of imatinib plus hydroxyurea in patients with progressive/recurrent meningioma. A total of 21 patients with progressive/recurrent meningioma were enrolled in this dual center, single-arm, phase II trial. All patients received 500 mg of hydroxyurea t...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Reardon, David A., Norden, Andrew D., Desjardins, Annick, Vredenburgh, James J., Herndon, James E., Coan, April, Sampson, John H., Gururangan, Sridharan, Peters, Katherine B., McLendon, Roger E., Norfleet, Julie A., Lipp, Eric S., Drappatz, Jan, Wen, Patrick Y., Friedman, Henry S.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2011
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3616615/
https://ncbi.nlm.nih.gov/pubmed/21938530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-011-0687-1
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller